The foundation of this partnership rests on a multifaceted framework that facilitates interdisciplinary research, joint faculty appointments, and an unprecedented sharing of cutting-edge laboratory infrastructure. By consolidating their scientific capabilities, TIBI and KGI will harness synergistic expertise across diverse yet interrelated domains, creating an ecosystem where pioneering technologies can be developed and rapidly transitioned from conceptualization to clinical implementation. This strategic coalition is enhanced by mutual access to core facilities, including specialized instrumentation platforms and preclinical animal research resources, which are essential for the rigorous evaluation and validation of novel biomedical technologies.

Central to the partnership’s mission is the elevation of student training and mentorship programs, reflecting a deep commitment to cultivating the next generation of biomedical innovators. Doctoral candidates at KGI will have enhanced access to Terasaki Institute laboratories, allowing immersive, hands-on research experiences under the guidance of leading principal investigators who are at the forefront of their fields. This collaborative training environment aims to foster a rich intellectual milieu where interdisciplinary approaches flourish, equipping emerging scientists with the skills and knowledge necessary to navigate the complexities of modern biomedical challenges.

From a research perspective, the alliance is designed to stimulate joint proposals for competitive grants, enabling researchers from both institutions to secure pivotal funding that supports ambitious, high-impact projects. In addition, co-authorship of scholarly publications and patent applications will reinforce the academic and translational significance of the collaborative efforts. This integrative approach underscores a shared ethos: advancing discovery not as isolated endeavors but through collective enterprise that amplifies the pace and scope of innovation in biomedical sciences.

Biomaterials—engineered substances designed to interface with biological systems—represent a cornerstone of this alliance’s scientific focus. By combining expertise in material science, cellular interactions, and bioengineering, researchers are poised to develop novel scaffolds and matrices that promote tissue regeneration and repair. These materials could revolutionize therapeutic strategies for a broad spectrum of conditions, from degenerative diseases to traumatic injuries, by providing tailored cellular environments that enhance healing and functional recovery.

Concurrently, the partnership prioritizes advances in cell engineering, wherein precise manipulation of cellular behaviors and functions enables the design of next-generation therapeutics. Techniques such as gene editing, stem cell programming, and synthetic biology are at the forefront, enabling the creation of engineered cells capable of performing complex therapeutic tasks, including targeted drug delivery, immune modulation, and tissue regeneration. This collaborative effort seeks to harness cutting-edge methodologies to push the boundaries of cellular therapies and regenerative medicine.

Drug delivery technologies, another principal focus area, are being revolutionized through this partnership by developing innovative platforms that improve the targeting, efficacy, and safety profiles of therapeutics. Researchers are investigating nanoparticle carriers, controlled release systems, and bioresponsive delivery mechanisms that synchronize therapeutic release with physiological cues. These advancements hold promise for overcoming longstanding challenges in pharmacokinetics and biodistribution, ultimately enabling personalized and precision medicine approaches tailored to individual patient needs.

The alliance also emphasizes medical device innovation, integrating engineering, materials science, and clinical insights to create novel diagnostic and therapeutic tools. By leveraging shared expertise, teams aim to develop devices that are not only more effective and biocompatible but also possess enhanced capabilities for real-time monitoring and intervention. These devices are critical in advancing minimally invasive procedures and improving patient outcomes across various medical disciplines.

Personalized medicine stands as a unifying theme throughout the partnership’s initiatives, focusing on the development of tailored diagnostic and therapeutic strategies that account for individual variability in genetics, environment, and lifestyle. By integrating data from multiple scientific domains, the collaboration seeks to refine patient-specific interventions that maximize therapeutic benefits while minimizing adverse effects. The amalgamation of innovative biomaterials, engineered cells, drug delivery systems, and medical devices under this personalized framework exemplifies a visionary approach to future healthcare.

To ensure effective governance and strategic vision, the partnership will be overseen by a joint Collaborative Research Steering Committee. This committee will coordinate research agendas, foster interdisciplinary dialogue, identify and secure funding opportunities, and rigorously evaluate scientific progress. The initial term of the agreement spans three years, with potential renewal contingent on demonstrable advancements and emerging collaborative opportunities, thereby maintaining agility in responding to evolving scientific frontiers.

Beyond research and education, the partnership also engages in community-building activities including scientific symposia, speaker series, and summer programs targeted at undergraduate and high school students. These initiatives aim to inspire and cultivate early interest in biomedical sciences, thereby strengthening the pipeline of future innovators. By fostering a broader scientific dialogue and promoting inclusivity in STEM fields, TIBI and KGI are contributing to a sustainable and dynamic biomedical research ecosystem.

The convergence of engineering, life sciences, and clinical applications encapsulated in this partnership sets a compelling precedent for how collaborative innovation can propel biomedical research into new realms of possibility. By embracing translational research principles, the Terasaki Institute for Biomedical Innovation and Keck Graduate Institute are not only advancing the frontiers of knowledge but also laying the groundwork for improved patient outcomes and societal health.

Stewart Han, President of the Terasaki Institute for Biomedical Innovation, articulated the vision underlying this alliance, emphasizing the power of combined institutional strengths in accelerating technology development that directly benefits patient care. Meanwhile, Dr. Loren Martin, Associate Vice Provost of Research at KGI, highlighted the indispensable role of collaborative partnerships in bridging the gap between laboratory discoveries and real-world applications.

As this partnership unfolds, the biomedical community will be closely observing its outcomes, anticipating novel therapeutics, advanced training paradigms, and a strengthened translational research infrastructure. Such endeavors are critical in an era where biomedical challenges are increasingly complex and require integrated approaches that transcend traditional disciplinary boundaries.

Ultimately, the collaboration between TIBI and KGI exemplifies a forward-thinking model that melds innovation with education and clinical relevance, heralding a new epoch in biomedical science where shared goals and unified efforts drive meaningful advances for global health.

Subject of Research:
Biomedical innovation focusing on biomaterials, cell engineering, drug delivery technologies, medical devices, and personalized medicine through interdisciplinary collaboration.

Article Title:
Terasaki Institute and Keck Graduate Institute Launch Strategic Partnership to Accelerate Biomedical Innovation

News Publication Date:
March 9, 2026

Web References:
https://mediasvc.eurekalert.org/Api/v1/Multimedia/e9a2135e-66be-4893-86e1-6f35e2f4b605/Rendition/low-res/Content/Public

Image Credits:
Terasaki Institute for Biomedical Innovation / Keck Graduate Institute

Keywords

Biomedical engineering, Scientific collaboration, Translational research, Biotechnology, Cell engineering, Biomaterials, Drug delivery, Medical devices, Personalized medicine, Interdisciplinary research, Scientific innovation, Graduate education

A groundbreaking solution has emerged from the Institute of Science and Technology Austria (ISTA), where an interdisciplinary team has developed an innovative algorithm designed to navigate these challenges with remarkable efficiency. By integrating concepts from information theory, advanced mathematics, genomics, and software engineering, the team has created a method that surpasses previous computational techniques in both speed and precision. This new approach enables researchers to jointly analyze whole genome sequences at a scale previously unattainable.

The focal point of their research is a model complex trait, human height, which has long served as a paradigm for studying the genetic architecture of complex traits. Human height is influenced by an extraordinarily large number of genetic variants—on the order of 17 million—which makes it an ideal benchmark for testing the algorithm’s capability. The researchers leveraged the extensive UK Biobank dataset, the world’s most comprehensive resource containing hundreds of thousands of whole-genome sequences from anonymized participants, to validate their approach.

Traditional methodologies typically dissect the dataset into smaller fragments, analyzing each segment separately before synthesizing the results. In contrast, the newly developed “genomic Vector Approximate Message Passing” (gVAMP) algorithm operates under a fundamentally different principle known as joint estimation. This approach simultaneously accounts for the influence of all genetic variants across the entire genome on the trait of interest, thereby capturing complex interactions that fragmentary methods might miss. This innovation allows gVAMP to provide a holistic overview of genetic effects with enhanced interpretability and accuracy.

At the core of gVAMP lies the approximate message passing (AMP) framework—a recent mathematical construct that offers a principled way to perform inference in large, complex datasets. ISTA researcher Marco Mondelli, a key contributor to AMP’s foundational theory, guided the adaptation of this framework to genomic data. The gVAMP algorithm extends AMP’s capabilities, tailored specifically to handle the immense dimensionality and correlation structure characteristic of whole-genome sequence datasets.

The promise of gVAMP is not solely theoretical; it manifests in tangible performance improvements. When tasked with predicting human height from genomic data, gVAMP generated novel insights by identifying genetic variant contributions whose effects had not been previously quantified. The challenge, however, was how to benchmark these predictions in the absence of pre-existing datasets capturing such detailed genetic effect estimations. To address this, the ISTA team designed extensive data simulations, generating synthetic traits approximating the complexity of human height traits. By comparing gVAMP’s performance against established genomic analysis methods on these simulated datasets, they demonstrated superior accuracy and drastically reduced processing times.

Beyond its predictive prowess, gVAMP shines in its interpretability—a critical feature for biomedical applications. The algorithm not only forecasts complex traits with heightened precision but also pinpoints specific genomic regions responsible for trait variability. This granularity provides invaluable biological insights, unveiling the intricate genetic architecture underlying complex characteristics. Such clarity could propel both fundamental genetic research and translational applications, helping to elucidate mechanisms driving traits and diseases alike.

Looking forward, the potential applications of gVAMP stretch into personalized medicine and diagnostic advancements. By enabling accurate joint genomic analyses at unprecedented scales, gVAMP could empower predictive models that inform on disease onset timing, progression severity, and symptom emergence. Further developments aim to integrate additional layers of biological data—including proteomic and epigenetic information—to capture biological complexity beyond genetic sequences alone. Incorporating such multi-omics perspectives promises to refine clinical decision-making, enabling tailored therapeutic interventions and optimized patient stratification in clinical trials.

Moreover, the versatility of gVAMP could extend into less conventional arenas such as forensic science. The ability to accurately predict phenotypic traits like height from DNA profiles retrieved at crime scenes represents a transformative tool for law enforcement and forensic investigations. This application highlights the broader societal impact of the algorithm, showcasing how cutting-edge computational methods can bridge research and real-world problem solving.

The success of this project underscores the power of interdisciplinary collaboration. The combined expertise in theoretical mathematics, computer science, genomic statistics, and software engineering catalyzed an algorithmic breakthrough. ISTA PhD student Al Depope, computer scientist Jakub Bajzik, mathematician Marco Mondelli, and genomic statistician Matthew Robinson exemplify how cross-domain approaches fuel innovation. Their joint supervision and integration of diverse skill sets facilitated a methodological leap forward in computational genomics.

In summary, the gVAMP algorithm stands at the forefront of computational genomics, delivering a scalable, precise, and interpretable solution for analyzing whole-genome sequence data. By redefining the boundaries of data-driven genetic inference, it opens new avenues for understanding human biology, advancing personalized healthcare, and potentially enhancing forensic methodologies. As research progresses, gVAMP’s framework is poised to become a foundational tool in the era of big genomic data.

Subject of Research: Cells

Article Title: Joint modelling of whole genome sequence data for human height via approximate message passing

News Publication Date: 18-Feb-2026

Web References:
https://doi.org/10.1016/j.xgen.2026.101162

References:
Al Depope, Jakub Bajzik, Marco Mondelli, and Matthew R. Robinson. 2026. Joint modelling of whole genome sequence data for human height via approximate message passing. Cell Genomics. DOI: 10.1016/j.xgen.2026.101162

Image Credits: © ISTA

Keywords: Human genetics, Population genetics, Data sets, Big data, Data points, Information retrieval, Information processing, Data storage, Databases, Data analysis, DNA, Genomics, Phenotypes, Algorithms, Mathematics, Information theory

The study, conducted by Kealy and Good-Jacobson, surfaces amidst a growing interdisciplinary effort to harness the unique properties of nanoparticles in biomedical applications. Historically, conventional vaccine approaches have relied heavily on singular antigens to provoke immune responses; however, the multiplicity of pathogens and their variants necessitates more dynamic solutions. By leveraging the non-covalent assembly method, the researchers have successfully demonstrated a sophisticated technique that overcomes the limitations of traditional covalent linkages, which can often hinder the effectiveness and flexibility of vaccine formulations.

Central to their findings is the careful selection of epitopes that can be loaded onto the nanoparticle surface. This involves understanding the physicochemical properties of both the epitopes and the nanoparticles used. The researchers meticulously detailed their criteria for selecting epitopes, considering factors such as solubility, charge, and size, which ultimately influence how well these molecules associate with each other and interact with the immune system.

Moreover, the study emphasizes the role of nanoparticle characteristics, such as size, shape, and surface chemistry in achieving optimal epitope presentation. The authors highlight that the right nanoparticle can significantly enhance the uptake of epitopes by antigen-presenting cells, leading to a more efficient activation of T and B cells, which are central players in immune responses. Therefore, by modifying just a few parameters, the researchers managed to create a versatile platform capable of targeting a range of pathogens, from viral to bacterial agents.

The immune system’s complexity poses a significant challenge for vaccine developers. To tailor vaccines that can effectively stimulate a robust immune response, the researchers investigated how various combinations of epitopes interacted with the immune system. This approach enables the fine-tuning of immune responses, allowing the assembly of epitopes that could either enhance activation or encourage tolerance, ultimately guiding the immune system’s memory formation and subsequent responses to reinfection.

One of the most compelling aspects of this research centers on the use of nanoparticle carriers for sequential epitope presentation. The authors demonstrate that by varying the timing and delivery of different epitopes, they can manipulate immune outcomes. This sequential delivery can be pivotal in generating long-lasting immunity and in combating pathogens that can mutate, such as those responsible for certain viral diseases.

Further investigations revealed that the method could be potentially expanded to create personalized vaccine strategies. By assembling highly specific epitopes that reflect a patient’s unique immunological profile, it may be possible to design tailored therapies that enhance vaccine efficacy. This could revolutionize our approach to vaccines, making treatments more effective against increasingly prevalent and resistant strains of infectious diseases.

In the context of infectious diseases, the enhancements offered by this nanoparticle approach could reshape public health responses. The ability to combine multiple targeted antigens into a single formulation means that vaccines could be developed more rapidly, addressing emerging public health threats with agility. The authors propose that the flexibility of this method could facilitate faster vaccine development pathways, ultimately saving lives in critical situations.

Notably, the non-covalent nature of the assembly process provides additional benefits concerning regulatory approval and manufacturing scalability. Unlike conventional approaches that require extensive modification processes, the simplicity and efficiency of this new method streamline production and reduce potential costs. As these advances unfold, the implications for community health could be profound, particularly in under-resourced settings where rapid response capabilities are crucial.

As the world grapples with the challenges of vaccine accessibility and rapid development, this research shines a light on the hope that nanotechnology holds in modern medicine. The study makes a significant contribution not only to the field of vaccinology but also to the broader realm of immunotherapy, potentially providing new strategies to mitigate diseases ranging from cancer to autoimmune disorders.

In conclusion, the findings presented by Kealy and Good-Jacobson signify an exciting milestone in the ongoing journey toward effective vaccine development. By overcoming traditional hurdles associated with epitope display through ingenious nanoparticle design, the researchers set the stage for a new era of vaccinations that promise improved efficacy and broader protection against a myriad of diseases.

With the incorporation of multiple epitopes on a single nanoparticle platform, this technology not only enhances the immune response but also incurs a substantial leap in our ability to respond to disease outbreaks. As researchers continue to build on this promising work, the potential applications extend far beyond infectious disease vaccines, forging a path towards innovative therapeutic solutions in the landscape of medicine.

The advancement of this non-covalent assembly presents tantalizing opportunities for both academia and industry. It enables a collaborative convergence of biotechnology, materials science, and immunology, fostering interdisciplinary innovations that could redefine therapeutic interventions. As work on this technology progresses, the global scientific community watches with keen interest, eager to leverage these insights into concrete applications that can significantly impact public health.

In summation, this transformative research alludes to a future where the hurdles of vaccine development may soon be surmountable, enhanced by the dynamic capabilities offered by nanoparticle technology and the clever engineering of epitope assembly. Through concerted efforts and collaboration, the path forward appears clearer, promising an arsenal of vaccines designed to save lives and protect global health against ever-evolving threats.

Subject of Research: Non-covalent assembly of multiple epitopes onto a single nanoparticle

Article Title: Non-covalent assembly of multiple epitopes onto a single nanoparticle.

Article References:

Kealy, L.C., Good-Jacobson, K.L. Non-covalent assembly of multiple epitopes onto a single nanoparticle.
Nat. Biomed. Eng (2025). https://doi.org/10.1038/s41551-025-01530-5

Image Credits: AI Generated

DOI: 10.1038/s41551-025-01530-5

Keywords: nanoparticle technology, vaccine development, epitopes, immune response, immunotherapy, infectious diseases, non-covalent assembly.

The CPRIT grant supporting Wittung-Stafshede’s appointment is part of a broader $67 million investment by the agency to fund cutting-edge cancer research across Texas institutions. This funding surge aims to accelerate scientific discovery in cancer prevention, diagnosis, and therapy. Wittung-Stafshede’s expertise lies at the crucial intersection of biophysics, metalloprotein chemistry, and cancer metastasis, making her an invaluable asset for Rice’s drive to deepen its biomedical research capabilities.

Wittung-Stafshede’s prior tenure at Rice as an associate professor of biosciences between 2004 and 2008 laid the foundation for her enduring connection to the university. She expressed enthusiasm for her return, highlighting the unparalleled collaborative environment Rice offers, especially through proximity to the Texas Medical Center, one of the world’s foremost biomedical hubs. This environment promises fertile ground for interdisciplinary synergies bridging chemistry, biology, and clinical research.

Central to Wittung-Stafshede’s scientific inquiry is the study of metalloproteins—protein molecules that bind metal ions such as copper, fundamental to maintaining cellular homeostasis. Her research elucidates the paradoxical role these proteins play in cancer progression. While essential to normal physiology, copper-binding metalloproteins can inadvertently facilitate tumor metastasis by supplying copper, a trace element pivotal for angiogenesis and cellular proliferation in malignant tissues.

Employing an array of sophisticated biochemical and spectroscopic methodologies, her laboratory interrogates the molecular mechanisms underpinning protein-metal interactions. Through spectroscopic techniques like circular dichroism, electron paramagnetic resonance, and nuclear magnetic resonance, her group deciphers the conformational dynamics and metal coordination chemistry that govern protein function and pathological aggregation.

One of the more profound implications of Wittung-Stafshede’s work is the potential to identify novel molecular targets that disrupt copper-dependent pathways exploited by metastatic cancer cells. By unraveling precisely how copper ions modulate the structural and functional properties of these proteins within cancerous environments, her research opens avenues for the design of inhibitors that could arrest metastasis, the leading cause of cancer mortality.

Beyond individual cancer types, Wittung-Stafshede’s research suggests that perturbations in copper metabolism may represent a unifying hallmark across diverse malignancies. This insight raises the tantalizing prospect of developing broad-spectrum anti-metastatic therapies grounded in fundamental bioinorganic chemistry, transcending traditional tumor classification paradigms.

In addition to her cancer-focused investigations, Wittung-Stafshede is deeply engaged with the molecular underpinnings of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Here, the spotlight shifts to metal-binding proteins that undergo pathological aggregation into amyloid fibrils—misfolded protein assemblies implicated in neuronal toxicity and cell death. Her work probes the mechanisms by which metal ions influence amyloid formation, morphology, and toxicity.

A fundamental enigma in neurodegeneration is why certain proteins begin aggregating and how different amyloid conformations emerge. Wittung-Stafshede emphasizes the necessity of basic mechanistic understanding to unravel triggers underpinning metal-induced amyloidogenesis, without which rational therapeutic intervention remains elusive. Her multidisciplinary approach integrates biophysical characterization with cellular models to illuminate these processes.

Since 2015, Wittung-Stafshede has held a professorship in the Chemical Biology division at Chalmers University of Technology in Sweden, where she also served as division head, fostering excellence in faculty development and gender equality initiatives. Her leadership and prolific scholarly output—exceeding 270 peer-reviewed publications—position her at the forefront of protein chemistry and biomedical research internationally.

Her scientific acumen is further evidenced by her membership on the Nobel Committee for Chemistry since 2020, reflecting her stature within the scientific community. Her career has been marked by pivotal faculty roles in prestigious institutions across North America and Europe, shaping the landscape of molecular life sciences through both research and mentoring.

CPRIT was established through visionary legislative and public support in Texas, reflecting a commitment to making the state a nexus for cancer innovation. Since its inception and latest funding expansion, the agency has deployed more than $3.7 billion in grants and successfully recruited over 300 leading researchers, including Wittung-Stafshede, solidifying Texas as a global leader in cancer research.

Pernilla Wittung-Stafshede’s appointment at Rice represents not just a faculty hire but a strategic enhancement of the university’s ability to tackle some of the most intractable challenges in cancer and neurodegeneration. Her integrative, mechanism-driven approach to biophysics and protein chemistry stands to yield groundbreaking insights with profound translational implications, driving forward the frontiers of science and medicine.

Subject of Research: Molecular mechanisms of cancer metastasis and neurodegenerative diseases focusing on metalloproteins and amyloid aggregation.

Article Title: Renowned Biophysicist Pernilla Wittung-Stafshede Joins Rice University with $6 Million CPRIT Grant to Advance Cancer and Neurodegeneration Research

Web References:
– https://cprit.texas.gov/grants-funded
– https://www.cprit.texas.gov/news-events/articles/state-cancer-agency-awards-68-million-in-research-grants-to-texas-institutions/

Image Credits: Photo by Johan Wingborg

Over the past decade, the Human Islet Research Network (HIRN), established by the National Institute of Diabetes and Digestive and Kidney Diseases in 2014, has made substantial strides in unraveling the complexities of type 1 diabetes pathogenesis. Spearheaded by City of Hope’s John Kaddis, the interdisciplinary HIRN consortium has developed innovative in vitro and in vivo systems that elucidate beta cell behavior within their native microenvironment. These advances allow scientists to model disease progression more accurately, employing novel technologies to dissect beta cell loss, immune interactions, and mechanisms of cell replacement. Despite these advancements, critical gaps remain in understanding the precise triggers for autoimmune beta cell destruction and how best to intercept these processes before the onset of clinical disease. The network emphasizes shared data platforms and collaborative training to foster cross-disciplinary solutions aimed at preventing and ultimately curing type 1 diabetes.

Emerging epidemiological evidence highlights the impact of obesity on multiple myeloma progression, particularly in individuals with the precursor lesion monoclonal gammopathy of undetermined significance (MGUS). Research led by Lawrence Liu at City of Hope meticulously analyzed longitudinal body mass index (BMI) data from nearly 22,500 MGUS patients to quantify the risk attributed to sustained elevated BMI. Their findings reveal a compelling correlation between prolonged exposure to overweight or obese BMI ranges and an increased likelihood of progression to full-blown multiple myeloma. Participants maintaining a BMI above 25 after diagnosis demonstrated a significantly elevated risk of malignancy evolution, underscoring the crucial importance of weight management in mitigating cancer risk. This study represents a paradigm shift in recognizing metabolic factors as modifiable determinants in hematologic cancer progression.

In the realm of metastatic colorectal cancer (mCRC), precision medicine continues to evolve with sophisticated biomarker-driven approaches to guide therapeutic decisions. Investigators at City of Hope, led by Ajay Goel, validated a revolutionary liquid biopsy platform known as EXONERATE to predict patient responses to epidermal growth factor receptor (EGFR) inhibitors, specifically panitumumab and cetuximab. Employing genome-wide small RNA sequencing of circulating exosomes and cell-free microRNAs, the assay identifies molecular signatures indicative of therapeutic efficacy. Crucially, this technology accounts for tumor heterogeneity associated with primary tumor sidedness, a known determinant of EGFR inhibitor response. The assay demonstrated robust predictive value for progression-free and overall survival across diverse patient populations, offering an unprecedented non-invasive tool for real-time treatment stratification in mCRC management.

Immune checkpoint blockade has transformed oncologic care, yet the heterogeneity of patient response remains a formidable challenge. Targeting this, Kelly Mahuron and colleagues at City of Hope embarked on an intricate molecular characterization of tumor infiltrating lymphocytes (TILs) within advanced melanoma samples to identify biomarkers predictive of anti-PD-1 antibody efficacy. Their seminal work employing single-cell RNA sequencing delineated a unique CD8+ TIL subset expressing high levels of PD-1 and CTLA-4 receptors, termed CP^Hi TILs. Patients harboring ≥20% CP^Hi TILs exhibited markedly improved objective response rates and survival outcomes following PD-1 monotherapy. This pioneering biomarker assay holds transformative potential for refining patient selection in immunotherapy, enabling clinicians to tailor treatments based on intratumoral immune cell phenotypes and thereby maximizing therapeutic benefit while minimizing unnecessary toxicity.

Cardiotoxicity remains a critical long-term concern for pediatric cancer survivors, whose growing population faces significant risks for treatment-related cardiovascular disease. A recent scientific statement from the American Heart Association, co-authored by City of Hope’s Saro Armenian, addresses emerging cardio-oncology challenges in this vulnerable group. Reflecting on decades of research, the statement underscores the deleterious effects of anthracycline chemotherapy and chest radiotherapy—cornerstones of pediatric oncology—on cardiac function. Advances in dose optimization, cardioprotective agents, and modern radiotherapy techniques have ameliorated some risks but novel therapies, including small-molecule inhibitors and immunotherapies, introduce new cardiotoxicity profiles. The comprehensive review advocates for equitable long-term surveillance, rehabilitation through structured physical activity, and seamless transition from pediatric to adult cardiology care to improve cardiovascular outcomes in childhood cancer survivors.

In efforts to counteract disease progression in chronic myeloid leukemia (CML), researchers at City of Hope led by Bin Zhang and Guido Marcucci have uncovered a novel immune-evasion mechanism operative during the transition to blast crisis (BC). Their study, published in Nature Communications, elucidates how acquired deficiency of microRNA miR-142 precipitates loss of cytotoxic T cells essential for anti-leukemic immunity. The miR-142 deficit simultaneously facilitates leukemic stem cell immune escape, thereby accelerating malignant transformation. Remarkably, the team developed a synthetic miR-142 mimic, M-miR-142, capable of restoring immune surveillance when administered alone or alongside monoclonal antibodies and tyrosine kinase inhibitors. Preclinical trials in murine models demonstrated prolonged survival, offering a promising therapeutic avenue to forestall BC progression and improve patient prognosis through immune modulation.

City of Hope also proudly celebrates the outstanding achievements of its scientific community. Notably, Dr. Ravi Salgia’s recognition as a Highly Ranked Scholar — Lifetime — for contributions to lung cancer research highlights the institution’s leadership. The 2025 American Association for Cancer Research (AACR) annual meeting further honored City of Hope researchers including Daniel D. Von Hoff for his unwavering dedication to cancer research and clinical care, Enrique Velazquez Villarreal for his minority scholar award recognition, and emerging scientists Kimya Karimi, Francisco Carranza, Eric Medina, and Isaac Bishara for their promising work in cancer research. These accolades attest to the vibrant and diverse scientific talent driving innovation at City of Hope.

In funding news, Ling Li, Ph.D., was awarded a prestigious $3.58 million National Cancer Institute grant for her innovative study targeting adenosine monophosphate (AMP) synthesis pathways to overcome resistance to BH3 mimetics in acute myeloid leukemia (AML). This research holds potential to surmount one of the major obstacles in AML therapy—the development of drug resistance—by exploiting metabolic vulnerabilities within leukemic cells, thereby enhancing the efficacy of pro-apoptotic agents.

City of Hope’s integrated research and clinical care model remains a cornerstone of its mission to revolutionize outcomes for patients afffected with cancer and diabetes. Its National Cancer Institute-designated comprehensive cancer center, consistently ranked among the top five in the United States, exemplifies excellence in multidisciplinary innovation, combining translational research, cutting-edge clinical trials, and an expansive network of care delivery. Through synergy with affiliated organizations such as the Translational Genomics Research Institute and AccessHope™, City of Hope continues to pioneer breakthroughs — from synthetic insulin production to monoclonal antibody therapeutics — redefining the standard of medical care.

Harnessing advanced molecular technologies, collaborative scientific inquiry, and clinical acumen, City of Hope’s researchers pave the way for precision medicine and immunotherapy strategies tailored to individual patient biology. Their recent discoveries in disease biomarkers, immune modulation, and metabolic regulation not only elucidate fundamental disease processes but also herald novel therapeutic paradigms. As the institution fuels this momentum, the prospects for improved prevention, diagnostic, and treatment modalities across oncology and metabolic disease grow exponentially, offering renewed hope for patients worldwide.

Subject of Research: Diabetes, Multiple Myeloma, Metastatic Colorectal Cancer, Immune Checkpoint Inhibitor Response, Pediatric Cardiovascular Toxicity, Chronic Myeloid Leukemia, Cancer Therapeutics, Biomarkers

Article Title: City of Hope Research Spotlight: Advances in Diabetes, Cancer Biology, Immunotherapy, and Survivorship

News Publication Date: 2025

Web References:

• City of Hope Research Spotlight Feed: https://www.cityofhope.org/about-city-of-hope/newsroom/research-spotlight/feed
• Diabetes Journal Article: https://doi.org/10.2337/db25-0097
• JAMA Network Open Paper: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2830028
• Clinical Cancer Research Paper: https://aacrjournals.org/clincancerres/article-abstract/31/6/1002/753268/An-Exosome-Based-Liquid-Biopsy-Predicts-Depth-of
• Cancer Research Paper: https://aacrjournals.org/cancerres/article/doi/10.1158/0008-5472.CAN-23-3918/753249/Single-Cell-Analyses-Reveal-a-Functionally
• Circulation Review Paper: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001308
• Nature Communications Paper: https://www.nature.com/articles/s41467-025-56383-y

References: Included within the text as links to primary scientific publications.

Keywords: Cancer research, Diabetes research, Multiple Myeloma, Liquid biopsy, EGFR inhibitors, Immune checkpoint inhibitors, Pediatric cardio-oncology, Chronic myeloid leukemia, Biomarkers, Immunotherapy, Molecular diagnostics

At the heart of this development lies the research led by Ande Marini, a University of Pittsburgh alumnus and current postdoctoral scholar at Stanford University, alongside bioengineering luminaries David Vorp and Justin Weinbaum. Their pioneering work was recently published in ACS Applied Materials & Interfaces, detailing a chemical conjugation technique that blends biocompatible silk fibroin with magnetically responsive iron oxide nanoparticles. The method leverages glutathione, a tripeptide compound, to chemically bond the iron oxide nanoparticles onto the silk matrix, ensuring structural stability and magnetic responsiveness throughout the particle’s movement within the body.

The choice of silk as a carrier material is strategic and innovative. Beyond its FDA-approved biocompatibility, silk fibroin possesses mechanical strength, biodegradability, and versatility in processing. By harnessing these properties, the researchers have created a platform that offers safe, controlled delivery mechanics with minimal immunogenic response. Embedding magnetically responsive iron oxide nanoparticles within this silk matrix introduces a capacity to manipulate the particles externally using magnetic fields, paving the way for noninvasive, targeted therapy applications.

One of the primary motivations for developing SIMPs stems from the urgent need to enhance treatments for abdominal aortic aneurysms (AAA), a life-threatening vascular disorder responsible for approximately 10,000 fatalities annually in the United States alone. Conventional AAA management often necessitates invasive surgical procedures. By contrast, SIMPs enable localized delivery of regenerative therapeutic agents—particularly extracellular vesicles (EVs)—designed to modulate cell signaling and repair mechanisms at the aneurysm site, potentially stabilizing the diseased aortic wall without surgery.

Extracellular vesicles are natural lipid-bound carriers produced by cells, acting as messengers to facilitate intercellular communication. Loading these vesicles onto SIMPs represents a sophisticated method to concentrate reparative signals precisely where they are needed. The team envisions a delivery approach where SIMPs, infused with EV cargo, are magnetically guided through the bloodstream and positioned adjacent to the aneurysm, thereby maximizing therapeutic efficacy while minimizing systemic side effects.

The fabrication process for these magnetic silk microparticles exemplifies the fruitful collaboration across multiple engineering disciplines. The nano-engineering expertise of Mostafa Bedewy and his former PhD student Golnaz Tomaraei was indispensable to the creation of iron oxide nanoparticles tailored for magnetic manipulation. These particles measure approximately one-hundred-thousandth the width of a human hair—a nanoscale dimension that confers unique magnetic properties appealing for precise medical applications.

At this scale, nanoparticles exhibit superparamagnetism, a phenomenon enabling strong magnetic responses without residual magnetization, critical for preventing aggregation in the circulatory system. By chemically conjugating these nanoparticles to regenerated silk fibroin via glutathione, researchers created a robust, magnetically steerable composite particle. This design contrasts with previous magnetically active materials that relied solely on physical adsorption, often resulting in nanoparticle detachment and loss of magnetic control during in vivo movement.

The implications of chemically bonded magnetic nanoparticles extend beyond stability. The covalent linkages enhance the particles’ magnetic mobility, allowing clinicians to externally guide SIMPs through complex vascular architectures to precise anatomical locations. This capability is transformative for targeted drug delivery, where spatial control over therapeutic payloads can dramatically improve treatment outcomes and reduce off-target toxicity.

While the current research demonstrates the effective creation and magnetic control of empty SIMP carriers, future steps will focus on incorporating therapeutic cargos. The flexibility of this platform permits loading a wide array of bioactive agents, including chemotherapeutic drugs for localized cancer treatment or regenerative molecules targeting cardiovascular tissues. Such versatility heralds a new paradigm where multifunctional biomaterials can address diverse pathologies through remotely controlled, site-specific delivery.

Concurrently, ongoing investigations in Bedewy’s nanomaterials laboratory aim to refine the molecular structure of these particles to tailor drug release kinetics finely. Modulating the interactions between silk fibroin and the therapeutic agents will enable sustained or triggered release profiles, further enhancing clinical utility. This intricate balancing of structural composition and functional responsiveness embodies the cutting edge of biomaterials science.

From a clinical translational perspective, the nascent SIMP technology could revolutionize treatment strategies for notoriously difficult-to-target conditions. Abdominal aortic aneurysms, vascular disorders, and solid tumors often pose substantial challenges due to their anatomical complexity and the systemic side effects associated with current therapies. Magnetically directable silk particles can circumvent these obstacles by delivering medications precisely where needed, thereby increasing treatment potency and patient safety.

Importantly, this project exemplifies the power of interdisciplinary collaboration. Experts in bioengineering, materials science, mechanical engineering, and cardiothoracic surgery converged to solve a complex biomedical problem. Their collective expertise enabled the design of a biomaterial system far greater than the sum of its parts, showcasing how integrated approaches accelerate innovation and impact patient care.

The journey from concept to realized technology underscores the transformative potential of biomaterials functionalized through chemical conjugation. By unlocking magnetic guidance within a biocompatible matrix, the researchers have opened novel frontiers in minimally invasive therapies. As these magnetically actuated silk microparticles progress toward clinical application, they promise to reshape the landscape of drug delivery and regenerative medicine fundamentally.

The fusion of nanotechnology and bioengineering embodied in SIMPs heralds a future where targeted medical interventions are not only more effective but also safer and less burdensome for patients. By marrying the precision of magnetic control with the versatility of silk-based carriers, this innovative platform could catalyze breakthroughs across a spectrum of diseases, from cardiovascular disorders to cancer.

In conclusion, the development of chemically conjugated silk iron microparticles represents a milestone in drug delivery technology. With ongoing research to optimize cargo loading and release, these magnetically steerable particles stand poised to transform therapeutic paradigms and offer new hope for conditions previously deemed intractable. The scientific community and patients alike await the exciting next chapters of this pioneering work.

Subject of Research: Not applicable

Article Title: Chemical Conjugation of Iron Oxide Nanoparticles for the Development of Magnetically Directable Silk Particles

News Publication Date: 3-Feb-2025

Web References:

• https://doi.org/10.1021/acsami.4c17536
• https://www.engineering.pitt.edu/subsites/faculty/vorp/vorp-lab/
• https://nanoproductlab.com/research/
• https://www.cdc.gov/heart-disease/about/aortic-aneurysm.html

References:
Marini, A. X., Vorp, D., Weinbaum, J., Bedewy, M., Tomaraei, G. (2025). Chemical Conjugation of Iron Oxide Nanoparticles for the Development of Magnetically Directable Silk Particles. ACS Applied Materials & Interfaces, DOI: 10.1021/acsami.4c17536.

Image Credits: Ande X. Marini

Keywords: Drug delivery systems, Nanotechnology, Nanoparticles, Magnetism, Silk, Cancer treatments, Cardiovascular disorders, Biomaterials

The latest study published in Light: Science & Applications showcases a diverse group of scientists—including chemists, physicists, biotechnologists, and neuroscientists—who have collaborated to innovate new tools for effective cell stimulation. Central to their findings is the introduction of water-soluble azobenzenes with unique push-pull characteristics, which heralds a departure from conventional photostimulation paradigms. Instead of relying solely on light as a stimulus, these azobenzenes facilitate modulation of the plasma membrane’s surface charge, providing a fresh mechanism to manipulate cellular responses without the need for invasive procedures.

The research team synthesized a series of new azobenzene compounds that incorporate an electron-acceptor group known as NO2, paired with varying numbers of cationic alkyl chains. These chains serve a dual purpose: they anchor the molecules within the cell membrane while also acting as electron donor groups. Through careful design, all synthesized molecules demonstrate an amphiphilic character, allowing them to interact effectively with lipid bilayers. This interaction is akin to previously reported photoswitchable lipids, creating exciting opportunities for cellular interaction.

Following extensive experimental work, the team undertook a rigorous screening process to identify azobenzene candidates possessing the best capabilities for integration into cell membranes and their efficacy in inducing light-dependent changes in membrane potential. The standout among these candidates was identified as MTP, which showed promising results. The team employed optical spectroscopy techniques to examine MTP’s push-pull nature and its response to isomerization within biological contexts.

The study revealed that upon photoexcitation, MTP can isomerize in approximately 10 picoseconds. This rapid transformation yields a six-fold increase in the lifetime of its cis form when present in sodium dodecyl sulfate compared to plain water. Supporting evidence from molecular dynamics simulations further elucidated the spatial distribution of these azobenzenes within membranes, suggesting that these compounds effectively partition into the lipid bilayer, ensuring their functionality.

Perhaps one of the most striking aspects of this research lies in the mechanism of action by which these azobenzenes operate. When exposed to light, the azobenzenes induce changes in the membrane’s surface charge, eliciting an electrokinetic response which promotes the movement of ions across the membrane. These induced movements correlate with experimentally recorded inward ionic currents, validating the proposed mechanism and underscoring the potential of MTP as a pioneering tool for optostimulation.

The authors of the study assert that MTP2 emerges as a noteworthy non-genetic optostimulation tool, facilitating precise modulation of the electrical characteristics inherent to the lipid membrane. In expanding on their findings, the researchers expressed that this novel mechanism broadens the spectrum of existing cell opto-stimulation modalities, which have conventionally revolved around opto-capacitance, electrostatic coupling, ion channel gating, or membrane poration.

An additional noteworthy feature of these newly developed molecules is their high water solubility, coupled with a rapid trans-cis interconversion rate. Crucially, these azobenzenes remain inactive in their dark state, which mitigates the potential for undesired cellular perturbations even in the absence of light stimulation. This trait signifies a substantial advancement, as many previous methods have suffered from issues related to persistent activity in the absence of a stimulus.

The experimental results delineate the efficacy of MTP in modulating membrane potentials across various biological models, including cell lines, primary neurons, and human-induced pluripotent stem cell-derived cardiomyocytes. Such a range of applications suggests that these azobenzenes may serve as versatile tools for manipulating cellular behavior in a variety of physiological and pathological contexts.

Furthermore, the implications of this research extend beyond simple cellular testing. The rapid optical-induced depolarization achieved through these azobenzenes, though not sufficient to directly trigger action potentials, opens the door to innovative applications in biomedical fields. One potential application involves utilizing sub-threshold optical stimulation to destabilize and even terminate re-entry-based arrhythmias, such as spiral waves in cardiac tissues. This advance could herald a new era in the treatment of cardiac rhythm disorders, offering physicians and patients alike a cutting-edge method for managing these complex conditions.

As this multidisciplinary team continues to explore the vast potential of these push-pull azobenzenes, their work undoubtedly sets a precedent for future studies aiming at integrating optical techniques in cell biology and neuroscience. It is a reminder of the power of collaborative science in overcoming the challenges presented by traditional methods and moving towards a more nuanced understanding of cellular processes.

In summary, the development of MTP and its unique approach to modulation of membrane potential represents a significant step forward in the quest to refine and enhance techniques for cellular stimulation. This innovative tool not only addresses existing limitations in neuronal therapy but also paves the way for broader applications in regenerative medicine, cardiac health, and potentially beyond. Researchers are now poised to investigate further applications and implications of this promising avenue of study, suggesting that the future of opto-stimulation holds boundless opportunities for advancing both basic research and therapeutic strategies.

Subject of Research: Development of membrane-targeted push-pull azobenzenes for optical modulation of membrane potential in cells.
Article Title: Membrane-targeted push-pull azobenzenes for the optical modulation of membrane potential
News Publication Date: [Insert Date Here]
Web References: [Insert Web Reference Here]
References: [Insert References Here]
Image Credits: Valentina Sesti, Arianna Magni et al.

Keywords

Optical stimulation, neuronal disorders, azobenzenes, membrane potential, biomedical research, non-genetic optostimulation, ion movement, cardiac arrhythmias, photophysical properties, drug development.